Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:35:58.178Z.
Calculation as of: 2026-10-06T13:35:58.178Z.
Quote observation: 2026-10-06T13:31:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7114033928f702054061c44125c31231f02474951b0017c983a2cfe9aac3c1c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$131.90M
Price/OCF Ratio
4.67
TTM Avg
39.51
3Y Avg
39.66
5Y Avg
39.66
Market Cap
$136.86M
Price/OCF Ratio
107.17
TTM Avg
51.49
3Y Avg
30.98
5Y Avg
26.48
Market Cap
$138.72M
Price/OCF Ratio
99.73
TTM Avg
456.46
3Y Avg
456.46
5Y Avg
456.46
Market Cap
$120.80M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cibus, Inc. (CBUS) | $129.76M | N/A | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $129.39M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $131.90M | 4.67 | 39.51 | 39.66 | 39.66 |
| LifeMD, Inc. (LFMD)vs › | $134.45M | N/A | 20.60 | 44.02 | 44.02 |
| enGene Holdings Inc. (ENGN)vs › | $124.27M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $136.86M | 107.17 | 51.49 | 30.98 | 26.48 |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.20M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.72M | 99.73 | 456.46 | 456.46 | 456.46 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $120.80M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $140.22M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
